PharmaCyte Biotech, Inc. (PMCB) · Nov 19, 2026 · Share issuance

PharmaCyte Biotech share exchange adds liquidity but delays Q/C maturity

Warrant exchange — 851,304 warrants exchanged for 4,982,272 shares; maturity extended to September 2, 2027

PharmaCyte Biotech’s share issuance filing converts part of its Q/C warrant position into common stock, while extending Q/C’s preferred maturity to September 2027.

PharmaCyte is still a non-revenue cancer-biotech company trying to clear a clinical hold on its pancreatic-cancer IND, while curtailing program spending and holding a sizable cash and investment portfolio. The filing is therefore a balance-sheet and portfolio event—not progress on the clinical program.

The Q/C investment becomes more directly monetizable, but not immediately cash. PharmaCyte will exchange 851,304 Q/C long-term warrants for 4,982,272 Q/C common shares. That replaces an option-like asset with common stock, potentially simplifying a future sale, but the shares still require Nasdaq approval and delivery; the agreement does not provide PharmaCyte with cash today. The exchange also covers only the specified warrants, with the remaining warrants continuing to exist.

FigureFiling figureComparison
Warrants exchanged (Agreement)851,304
Q/C common shares received (Agreement)4,982,272
Preferred maturity date (Series H Amendment)September 2, 2027March 2, 2027

The maturity extension gives Q/C more runway and protects PharmaCyte from an earlier liquidity event. PharmaCyte controls more than a majority of Q/C’s Series H preferred stock and consents to moving the maturity date from March 2, 2027 to September 2, 2027. 〔0〕 That is helpful for the counterparty and may improve the value or survivability of PharmaCyte’s Q/C position, but it also defers a potential repayment or conversion decision by six months.

The filing does not change PharmaCyte’s core operating bottleneck. There is no new financing for PharmaCyte, no FDA clinical-hold removal, no trial restart, and no change to its non-revenue development status. The shares are also not freely saleable immediately: PharmaCyte receives demand registration rights only after 90 days following closing, and the closing itself depends on actual share delivery and listing approval.

Bottom line: This modestly improves the form and potential liquidity of PharmaCyte’s Q/C investment while extending the counterparty’s runway. It is a small balance-sheet positive, not a change to the company’s stalled clinical story.

What to watch next

Closing upon Nasdaq approval and actual share delivery

Original filing on SEC EDGAR

More PharmaCyte Biotech, Inc. news

PharmaCyte Biotech share exchange adds liquidity but delays Q/C maturity | PMCB Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.